Dr McMillan and colleagues from Glasgow, Scotland undertook a study in order to examine the relationship between the systemic inflammatory response and the outcome in patients undergoing resection for ductal adenocarcinoma.
The researchers recorded the clinicopathological status, the pre- and postoperative systemic inflammatory response and survival in patients undergoing potentially curative resection for ductal adenocarcinoma of the head of the pancreas.
The research team included a total of 65 patients in the study.
The participants had all undergone resection of ductal adenocarcinoma of the head of pancreas between 1993 and 2001, and had pre- and postoperative measurements of C-reactive protein.
|Patients with a postoperative C-reactive protein 10 mg l-1 had a median survival of 21.5 months|
The researchers noted that the majority of patients had stage III disease (International Union Against Cancer Criteria, IUCC).
In addition, the research team found that the majority had positive circumferential margin involvement (R1), tumor size greater than 25 mm with perineural and lymph node invasion and died within the follow-up period.
The researchers performed multivariate analysis and found that tumor size, vascular invasion and postoperative C-reactive protein retained independent significance.
Those patients with a postoperative C-reactive protein 10 mg l-1 had a median survival of 21.5 months compared with 8.4 months in those patients with a C-reactive protein >10 mg l-1.
Dr McMillan concluded, "The results of the present study indicate that, in patients who have undergone potentially curative resection for ductal adenocarcinoma of the head of pancreas, the presence of a systemic inflammatory response predicts poor outcome."